Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib
| Autor: | William Pao, Vincent A. Miller, Murk-Hein Heinemann, Mark G. Kris, Barbara Pizzo, Dana L. Sachs, Leah Ben-Porat, Leslie B. Tyson, Robert T. Heelan, Neelam T. Shah |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Diarrhea
Male Drug Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment media_common.quotation_subject Antineoplastic Agents Eye Gefitinib Patient Education as Topic Carcinoma Non-Small-Cell Lung Internal medicine Carcinoma medicine Humans Drug Interactions Dosing Lung cancer media_common Chemotherapy business.industry Exanthema medicine.disease Rash respiratory tract diseases ErbB Receptors Radiography Quinazolines Female Non small cell medicine.symptom Lung Diseases Interstitial business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:165-174 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.04.057 |
| Popis: | Purpose The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non–small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. Methods This article reviews gefitinib’s indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. Results We present our recommendations for the management of rash and diarrhea caused by this agent. Conclusion This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|